Research programme: anticancer therapeutics - Avalon

Drug Profile

Research programme: anticancer therapeutics - Avalon

Alternative Names: Anticancer therapeutics research programme - Sanofi-Aventis/Avalon

Latest Information Update: 19 Aug 2008

Price : $50

At a glance

  • Originator Avalon Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 19 Aug 2008 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 21 Dec 2005 The collaboration between Avalon Pharmaceuticals and sanofi-aventis has expired
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form sanofi-aventis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top